# The prognostic marker NRIP1 is associated with tumor progression and immune infiltration in acute myeloid leukemia: NRIP1 is associated with tumor progression and immune infiltration

## TL;DR

NRIP1 is a new biomarker in acute myeloid leukemia linked to worse survival and immune cell infiltration, offering potential for better treatment strategies.

## Contribution

NRIP1 is identified as a novel prognostic marker and functional regulator in AML progression and immune infiltration.

## Key findings

- High NRIP1 expression in AML patients correlates with significantly shorter overall survival.
- NRIP1 is associated with infiltration of multiple immune cell types, suggesting a role in immune regulation.
- NRIP1 knockdown in AML cell lines reduces proliferation and induces apoptosis.

## Abstract

Acute myeloid leukemia (AML) is a clinically aggressive hematologic malignancy characterized by high relapse rates and treatment resistance, highlighting the need for novel biomarkers to improve clinical outcomes. In this study, we explore the roles of nuclear receptor-interacting protein 1 (NRIP1) in AML, focusing on its associations with tumor progression and immune infiltration. Analysis of public AML gene expression datasets reveals that NRIP1 expression is significantly increased in AML patients. Those with high NRIP1 expression have markedly shorter overall survival than those with low expression. Furthermore, NRIP1 expression is significantly associated with the infiltration of diverse immune cells, including B cells, dendritic cells, T cells, mast cells, eosinophils, and T helper cells, suggesting that NRIP1 may be a regulator of immune cell infiltration. Functional enrichment analysis indicates that NRIP1 and its interacting partners are involved in tumorigenesis, immune microenvironment remodeling, and metabolic reprogramming. Survival analysis confirms the prognostic value of NRIP1. Importantly, functional validation in AML cell lines confirms that
NRIP1 knockdown suppresses proliferation and induces apoptosis. Our study identifies NRIP1 as a multifaceted regulator that promotes AML by driving tumor progression, regulating immune cell infiltration, and modulating ferroptosis, highlighting its role as a novel prognostic biomarker.